Madrigal Pharmaceuticals, Inc. (MDGL)
NASDAQ: MDGL · IEX Real-Time Price · USD
287.24
+8.11 (2.91%)
At close: Jul 19, 2024, 4:00 PM
294.00
+6.76 (2.35%)
Pre-market: Jul 22, 2024, 4:17 AM EDT
Madrigal Pharmaceuticals Employees
Madrigal Pharmaceuticals had 376 employees as of December 31, 2023. The number of employees increased by 284 or 308.70% compared to the previous year.
Employees
376
Change (1Y)
284
Growth (1Y)
308.70%
Revenue / Employee
n/a
Profits / Employee
-$1,181,582
Market Cap
6.12B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 376 | 284 | 308.70% |
Dec 31, 2022 | 92 | 21 | 29.58% |
Dec 31, 2021 | 71 | 29 | 69.05% |
Dec 31, 2020 | 42 | 13 | 44.83% |
Dec 31, 2019 | 29 | 12 | 70.59% |
Dec 31, 2018 | 17 | 9 | 112.50% |
Dec 31, 2017 | 8 | 0 | - |
Dec 31, 2016 | 8 | -2 | -20.00% |
Dec 31, 2015 | 10 | -100 | -90.91% |
Dec 31, 2014 | 110 | -24 | -17.91% |
Dec 31, 2013 | 134 | 10 | 8.06% |
Dec 31, 2012 | 124 | 2 | 1.64% |
Dec 31, 2011 | 122 | 10 | 8.93% |
Dec 31, 2010 | 112 | -15 | -11.81% |
Dec 31, 2009 | 127 | -2 | -1.55% |
Dec 31, 2008 | 129 | -46 | -26.29% |
Dec 31, 2007 | 175 | 29 | 19.86% |
Dec 31, 2006 | 146 | 28 | 23.73% |
Jan 12, 2005 | 118 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
Grifols | 23,737 |
Acadia Healthcare Company | 23,500 |
Bausch + Lomb | 13,300 |
Elanco Animal Health | 9,800 |
Stevanato Group | 5,634 |
HealthEquity | 3,150 |
Glaukos | 907 |
Cytokinetics | 423 |
MDGL News
- 6 weeks ago - Madrigal Pharmaceuticals Announces New Data from the Phase 3 MAESTRO-NASH Study of Rezdiffra™ (resmetirom) Presented at the EASL Congress - GlobeNewsWire
- 2 months ago - Madrigal Pharmaceuticals Reports First-Quarter 2024 Financial Results and Provides Corporate Updates - GlobeNewsWire
- 3 months ago - Madrigal Statement on the Passing of Dr. Stephen Harrison - GlobeNewsWire
- 3 months ago - Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 4 months ago - Madrigal Pharmaceuticals Announces Pricing of Upsized $600 Million Public Offering - GlobeNewsWire
- 4 months ago - Madrigal Pharmaceuticals Announces Proposed Public Offering - GlobeNewsWire
- 4 months ago - Madrigal Pharma surges on FDA nod to first drug for fatty liver disease NASH - Reuters
- 4 months ago - FDA approves Madrigal Pharmaceuticals drug as first treatment for common NASH liver disease - CNBC